Quarterly report · Q2
4480.TEDINET S100ROAG
Period2023-01-01 → 2023-06-30
Filed2023-08-14
StandardJapan GAAP
ConsolidatedYes
Data checks14 of 14 passed
Key figures · 49
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥10.7bn | 2023-01-01 → 2023-06-30 | Cons. | Net sales |
| Revenue | ¥14.2bn | 2022-01-01 → 2022-12-31 | Cons. | Net sales (5-year summary) |
| Revenue | ¥7.0bn | 2022-01-01 → 2022-06-30 | Cons. | Net sales |
| Operating income | ¥2.4bn | 2023-01-01 → 2023-06-30 | Cons. | Operating income |
| Operating income | ¥1.3bn | 2022-01-01 → 2022-06-30 | Cons. | Operating income |
| Ordinary income | ¥2.8bn | 2023-01-01 → 2023-06-30 | Cons. | Ordinary income |
| Ordinary income | ¥1.5bn | 2022-01-01 → 2022-12-31 | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥1.4bn | 2022-01-01 → 2022-06-30 | Cons. | Ordinary income |
| Profit before tax | ¥2.8bn | 2023-01-01 → 2023-06-30 | Cons. | Income before income taxes |
| Profit before tax | ¥1.4bn | 2022-01-01 → 2022-06-30 | Cons. | Income before income taxes |
| Net income (owners) | ¥1.9bn | 2023-01-01 → 2023-06-30 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥1.0bn | 2022-01-01 → 2022-12-31 | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | ¥969m | 2022-01-01 → 2022-06-30 | Cons. | Profit loss attributable to owners of parent |
| Net income | ¥1.9bn | 2023-01-01 → 2023-06-30 | Cons. | Profit loss |
| Net income | ¥970m | 2022-01-01 → 2022-06-30 | Cons. | Profit loss |
| Total assets | ¥24.5bn | at 2023-06-30 | Cons. | Assets |
| Total assets | ¥21.8bn | at 2022-12-31 | Cons. | Assets |
| Total assets | ¥20.9bn | at 2022-06-30 | Cons. | Total assets (5-year summary) |
| Total liabilities | ¥7.3bn | at 2023-06-30 | Cons. | Liabilities |
| Total liabilities | ¥6.6bn | at 2022-12-31 | Cons. | Liabilities |
| Net assets / equity | ¥17.2bn | at 2023-06-30 | Cons. | Net assets |
| Net assets / equity | ¥15.2bn | at 2022-12-31 | Cons. | Net assets |
| Net assets / equity | ¥14.8bn | at 2022-06-30 | Cons. | Net assets (5-year summary) |
| Cash and deposits | ¥16.0bn | at 2023-06-30 | Cons. | Cash and deposits |
| Cash and deposits | ¥14.4bn | at 2022-12-31 | Cons. | Cash and deposits |
| Cash & equivalents | ¥15.9bn | at 2023-06-30 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥14.4bn | at 2022-12-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥14.5bn | at 2022-06-30 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥14.0bn | at 2021-12-31d | Cons. | Cash and cash equivalents |
| Operating cash flow | ¥2.8bn | 2023-01-01 → 2023-06-30 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | ¥2.0bn | 2022-01-01 → 2022-12-31 | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | ¥1.3bn | 2022-01-01 → 2022-06-30 | Cons. | Net cash provided by used in operating activities |
| Investing cash flow | −¥805m | 2023-01-01 → 2023-06-30 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | −¥751m | 2022-01-01 → 2022-12-31 | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | −¥366m | 2022-01-01 → 2022-06-30 | Cons. | Net cash provided by used in investment activities |
| Financing cash flow | −¥385m | 2023-01-01 → 2023-06-30 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | −¥927m | 2022-01-01 → 2022-12-31 | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | −¥449m | 2022-01-01 → 2022-06-30 | Cons. | Net cash provided by used in financing activities |
| EPS (basic) | ¥58.48 | 2023-01-01 → 2023-06-30 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥47.29 | 2023-04-01 → 2023-06-30d | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥31.77 | 2022-01-01 → 2022-12-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥30.32 | 2022-01-01 → 2022-06-30 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥31.29 | 2022-04-01 → 2022-06-30d | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (diluted) | ¥57.65 | 2023-01-01 → 2023-06-30 | Cons. | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥31.16 | 2022-01-01 → 2022-12-31 | Cons. | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥29.71 | 2022-01-01 → 2022-06-30 | Cons. | Diluted earnings per share (5-year summary) |
| Equity ratio | 69.9% | at 2023-06-30 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 69.1% | at 2022-12-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 70.2% | at 2022-06-30 | Cons. | Equity to asset ratio (5-year summary) |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 34
| Segment | Item | Period | Value |
|---|---|---|---|
| Reconciling Itemsreconciling | revenue | 2023-01-01 → 2023-06-30 | −¥1m |
| Reconciling Itemsreconciling | revenue intersegment | 2023-01-01 → 2023-06-30 | −¥1m |
| Reconciling Itemsreconciling | segment profit | 2023-01-01 → 2023-06-30 | −¥1.2bn |
| jpcrp040300-q2r_E33586-000Medical Platform Businessreportable segment | revenue | 2023-01-01 → 2023-06-30 | ¥2.9bn |
| jpcrp040300-q2r_E33586-000Medical Platform Businessreportable segment | revenue external | 2023-01-01 → 2023-06-30 | ¥2.9bn |
| jpcrp040300-q2r_E33586-000Medical Platform Businessreportable segment | segment profit | 2023-01-01 → 2023-06-30 | −¥38m |
| jpcrp040300-q2r_E33586-000New Business Development Servicesreportable segment | revenue | 2023-01-01 → 2023-06-30 | ¥178m |
| jpcrp040300-q2r_E33586-000New Business Development Servicesreportable segment | revenue external | 2023-01-01 → 2023-06-30 | ¥178m |
| jpcrp040300-q2r_E33586-000New Business Development Servicesreportable segment | segment profit | 2023-01-01 → 2023-06-30 | −¥121m |
| jpcrp040300-q2r_E33586-000Recruitment Platform Businessreportable segment | revenue | 2023-01-01 → 2023-06-30 | ¥7.7bn |
| jpcrp040300-q2r_E33586-000Recruitment Platform Businessreportable segment | revenue external | 2023-01-01 → 2023-06-30 | ¥7.7bn |
| jpcrp040300-q2r_E33586-000Recruitment Platform Businessreportable segment | revenue intersegment | 2023-01-01 → 2023-06-30 | ¥1m |
| jpcrp040300-q2r_E33586-000Recruitment Platform Businessreportable segment | segment profit | 2023-01-01 → 2023-06-30 | ¥3.8bn |
| Total Of Reportable Segments And Otherssegment total | revenue | 2023-01-01 → 2023-06-30 | ¥10.7bn |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2023-01-01 → 2023-06-30 | ¥10.7bn |
| Total Of Reportable Segments And Otherssegment total | revenue intersegment | 2023-01-01 → 2023-06-30 | ¥1m |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2023-01-01 → 2023-06-30 | ¥3.6bn |
| Reconciling Itemsreconciling | revenue | 2022-01-01 → 2022-06-30 | −¥1m |
| Reconciling Itemsreconciling | revenue intersegment | 2022-01-01 → 2022-06-30 | −¥1m |
| Reconciling Itemsreconciling | segment profit | 2022-01-01 → 2022-06-30 | −¥1.1bn |
| jpcrp040300-q2r_E33586-000Medical Platform Businessreportable segment | revenue | 2022-01-01 → 2022-06-30 | ¥1.5bn |
| jpcrp040300-q2r_E33586-000Medical Platform Businessreportable segment | revenue external | 2022-01-01 → 2022-06-30 | ¥1.5bn |
| jpcrp040300-q2r_E33586-000Medical Platform Businessreportable segment | segment profit | 2022-01-01 → 2022-06-30 | −¥224m |
| jpcrp040300-q2r_E33586-000New Business Development Servicesreportable segment | revenue | 2022-01-01 → 2022-06-30 | ¥160m |
| jpcrp040300-q2r_E33586-000New Business Development Servicesreportable segment | revenue external | 2022-01-01 → 2022-06-30 | ¥160m |
| jpcrp040300-q2r_E33586-000New Business Development Servicesreportable segment | segment profit | 2022-01-01 → 2022-06-30 | −¥24m |
| jpcrp040300-q2r_E33586-000Recruitment Platform Businessreportable segment | revenue | 2022-01-01 → 2022-06-30 | ¥5.3bn |
| jpcrp040300-q2r_E33586-000Recruitment Platform Businessreportable segment | revenue external | 2022-01-01 → 2022-06-30 | ¥5.3bn |
| jpcrp040300-q2r_E33586-000Recruitment Platform Businessreportable segment | revenue intersegment | 2022-01-01 → 2022-06-30 | ¥1m |
| jpcrp040300-q2r_E33586-000Recruitment Platform Businessreportable segment | segment profit | 2022-01-01 → 2022-06-30 | ¥2.6bn |
| Total Of Reportable Segments And Otherssegment total | revenue | 2022-01-01 → 2022-06-30 | ¥7.0bn |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2022-01-01 → 2022-06-30 | ¥7.0bn |
| Total Of Reportable Segments And Otherssegment total | revenue intersegment | 2022-01-01 → 2022-06-30 | ¥1m |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2022-01-01 → 2022-06-30 | ¥2.3bn |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 520
| Item | Context | Value | Unit |
|---|---|---|---|
| Year to quarter end consolidated statement of comprehensive income (text) | CurrentYTDDuration | Text · Plus | |
| Quarterly consolidated statement of cash flows (text) | CurrentYTDDuration | Text · Plus | |
| Notes accounting treatments specific to quarterly financial statements quarterly consolidated financial statements (text) | CurrentYTDDuration | Text · Plus | |
| Notes when there is significant seasonal fluctuation in sales or operating expenses (text) | CurrentYTDDuration | Text · Plus | |
| Major components of selling general and administrative expenses (text) | CurrentYTDDuration | Text · Plus | |
| Reconciliation of ending balance of cash and cash equivalents with account balances per balance sheet (text) | CurrentYTDDuration | Text · Plus | |
| Notes regarding dividend (text) | Prior1YTDDuration | Text · Plus | |
| Notes when there is significant changes in amounts of equity (text) | Prior1YTDDuration | Text · Plus | |
| Notes regarding dividend (text) | CurrentYTDDuration | Text · Plus | |
| Notes when there is significant changes in amounts of equity (text) | CurrentYTDDuration | Text · Plus | |
| Notes segment information etc quarterly consolidated financial statements (text) | CurrentYTDDuration | Text · Plus | |
| Footnotes regarding segment information table (text) | Prior1YTDDuration | Text · Plus | |
| Information about impairment loss of non current assets or goodwill etc for each reportable segment (text) | Prior1YTDDuration | Text · Plus | |
| Footnotes regarding segment information table (text) | CurrentYTDDuration | Text · Plus | |
| Information about impairment loss of non current assets or goodwill etc for each reportable segment (text) | CurrentYTDDuration | Text · Plus | |
| Notes revenue recognition quarterly consolidated financial statements (text) | CurrentYTDDuration | Text · Plus | |
| Notes per share information quarterly consolidated financial statements (text) | CurrentYTDDuration | Text · Plus | |
| Notes significant events after reporting period quarterly consolidated financial statements (text) | CurrentYTDDuration | Text · Plus | |
| Other information consolidated financial statements etc (text) | CurrentYTDDuration | Text · Plus | |
| Information about company which provides guarantee to reporting company (text) | FilingDateInstant | Text · Plus |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 14 of 14 passed
| balance sheet identity | pass |
| balance sheet identity | pass |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |